化疗相关神经毒性的多因素贡献因素
该多中心横断面研究纳入901例接受神经毒性抗癌治疗者,用临床分级、TNS与EORTC-CIPN20等多模态评估CIPN;37%有中度至重度CIPN,31%因CIPN需调整剂量,女性、高龄、糖尿病、较高BMI及既往神经毒性治疗与CIPN相关。
要点
- 女性与剂量限制性CIPN相关(OR 1.7)。
- 高龄、糖尿病、较高BMI及既往神经毒性治疗与治疗后CIPN相关。
- 这些治疗前即可获得的临床变量提示CIPN易感性。
核心结论
- 女性、高龄、糖尿病、较高BMI及既往神经毒性治疗与CIPN发生及严重程度相关。
研究设计与样本
- 横断面多中心研究,纳入901例接受神经毒性抗癌治疗者,中位年龄61岁,66%为女性,治疗后中位12个月评估。
主要发现
- 37%有中度至重度CIPN(临床分级≥2),31%因CIPN需调整剂量。
- 女性与剂量限制性CIPN相关(OR 1.7,95%CI 1.2-2.5)。
- 患者报告神经病变与高龄(β=3.9,95%CI 2.0-5.7)、糖尿病(β=3.3,95%CI 0.1-6.5)、超重(β=3.1,95%CI 0.9-5.2)、肥胖(β=3.8,95%CI 1.4-6.2)及既往神经毒性治疗(β=5.1,95%CI 1.3-8.9)相关。
- 临床分级与年龄(OR 3.0,95%CI 2.2-4.2)、超重(OR 2.1,95%CI 1.5-3.0)、肥胖(OR 1.6,95%CI 1.1-2.4)及既往神经毒性治疗(OR 2.9,95%CI 1.2-6.8)相关。
- 严重CIPN在各评估工具中均与高龄及既往神经毒性治疗相关。
关键数值与推荐
- 剂量限制性CIPN:女性OR 1.7(95%CI 1.2-2.5)。
- 严重CIPN(EORTC-CIPN20):高龄OR 1.9(95%CI 1.3-2.6),既往神经毒性治疗OR 1.9(95%CI 1.0-3.4)。
- 严重CIPN(TNS):高龄OR 3.2(95%CI 2.2-4.8),既往神经毒性治疗OR 2.0(95%CI 1.1-3.7)。
- 严重CIPN(临床分级):高龄OR 1.8(95%CI 1.3-2.4),既往神经毒性治疗OR 2.1(95%CI 1.2-3.7)。
临床怎么用
- 治疗开始前可评估年龄、性别、BMI、糖尿病及既往神经毒性治疗史以识别CIPN高危者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a complex and dose-limiting toxicity of cancer treatment leading to increased disability and reduced quality of life. Inconsistent use of outcome measures in previous studies have limited our ability to identify clinical risk factors for CIPN. This study aimed to use a comprehensive multimodal battery of neuropathy assessment to investigate the association between clinical variables and CIPN in individuals treated with neurotoxic cancer treatment. METHODS: We conducted a cross-sectional, multisite study of individuals who had received neurotoxic treatments from oncology centers in Australia (taxanes, platinum, vinca alkaloids, bortezomib, and thalidomide). CIPN was assessed through clinical grading, neurologic evaluation (Total Neuropathy Score [TNS], sural nerve conduction studies), and patient-reported outcome measure (European Organization for Research and Treatment of Cancer Quality of Life Chemotherapy-Induced Peripheral Neuropathy Questionnaire [EORTC-CIPN20]). Clinical variables included demographic (age, sex), metabolic (body mass index [BMI], diabetic status), and medical history (preexisting peripheral neuropathy, prior neurotoxic treatment). Dose information was extracted from clinical notes to identify dose modification of neurotoxic treatments due to CIPN. Least absolute shrinkage and selection operator (LASSO) regression was used to identify candidate variables, followed by multivariable regression to construct final models. The results were presented as odds ratio (OR) or β (95% CI). RESULTS: The study included 901 individuals (median age 61 [interquartile range 19] years, 66% female) assessed 12 (median; interquartile range 18) months postneurotoxic treatment. In total, 37% had moderate-to-severe CIPN (n = 337, clinical grade ≥2), and 31% required dose modification due to CIPN. Multivariable logistic regression identified female sex (OR 1.7, 95% CI 1.2-2.5) to be associated with dose-limiting CIPN. Post-treatment CIPN was evaluated using multiple assessment tools. Patient-reported neuropathy was associated with older age (β = 3.9, 95% CI 2.0-5.7), diabetes (β = 3.3, 95% CI 0.1-6.5), higher BMI (overweight β = 3.1 [95% CI 0.9-5.2], obese β = 3.8 [95% CI 1.4-6.2]), and prior neurotoxic treatment (β = 5.1, 95% CI 1.3-8.9). Similar factors were associated with neurologic evaluation (TNS, sural amplitude). Clinical grading was associated with age (OR 3.0, 95% CI 2.2-4.2), higher BMI (overweight OR 2.1 [95% CI 1.5-3.0], obese OR 1.6 [95% CI 1.1-2.4]), and prior neurotoxic treatment (OR 2.9, 95% CI 1.2-6.8). Variables associated with severe CIPN (defined as highest quartile scores or moderate/severe clinical grading) across all assessment tools included older age (EORTC-CIPN20 OR 1.9 [95% CI 1.3-2.6], TNS OR 3.2 [95% CI 2.2-4.8], clinical grading OR 1.8 [95% CI 1.3-2.4]), and prior neurotoxic treatment (EORTC-CIPN20 OR 1.9 [95% CI 1.0-3.4], TNS OR 2.0 [95% CI 1.1-3.7], clinical grading OR 2.1 [95% CI 1.2-3.7]). DISCUSSION: CIPN is a significant toxicity that affects patients' ability to receive anticancer therapies and continues to affect long-term survivorship. We identified clinical variables that are readily available at beginning of treatment, which suggest increasing susceptibility to developing dose-limiting, post-treatment, and severe CIPN.
引用
- Li T, Timmins HC, Horvath LG, et al. Multifactorial Contributors to Dose Limiting and Post-Treatment Neurologic Toxicity During Chemotherapy Treatment. Neurology. 2026. PMID: 42814908. doi:10.1212/WNL.0000000000218599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。